drugset / Trial / NCT01540682
MLN8237 in Head and Neck Cancer
NaSingle-groupTreatment
Summary
This study will evaluate the initial safety and effectiveness of an investigational drug, MLN8237, added to routine radiation therapy and cetuximab in patients with head and neck cancer. This study will also determine the highest dose of MLN8237 that can be given together with cetuximab and radiation therapy without causing severe side effects.
Timeline
- Start
- 2012-02
- Primary completion
- 2015-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alisertib | Small molecule | 30 mg | Oral |
| Subject | Alisertib | Small molecule | 40 mg | Oral |
| Subject | Alisertib | Small molecule | 50 mg | Oral |
| Background | Cetuximab | Monoclonal antibody | — | — |